Suggested remit: To appraise the clinical and cost effectiveness of vimseltinib within its anticipated marketing authorisation for adults with symptomatic tenosynovial giant cell tumour when surgery is unsuitable.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Decision publication date:
- 23 September 2024
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Criteria within the (VPAG) met as a new active substance.
- Process:
- STA Standard
- ID number:
- 6736
Project Team
- Project lead
- scopingta@nice.org.uk
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 July 2026 - 19 August 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6736 |
| 22 July 2026 | In progress. Scoping commencing |
| 23 September 2024 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual